- Home
- MODD vs VRCA Comparison
MODD vs VRCA Comparison
Compare MODD & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- VRCA
- Stock Information
- Founded
- MODD 1998
- VRCA 2013
- Country
- MODD United States
- VRCA United States
- Employees
- MODD N/A
- VRCA N/A
- Industry
- MODD Industrial Specialties
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- VRCA Health Care
- Exchange
- MODD Nasdaq
- VRCA Nasdaq
- Market Cap
- MODD 46.3M
- VRCA 43.0M
- IPO Year
- MODD N/A
- VRCA 2018
- Fundamental
- Price
- MODD $0.83
- VRCA $0.50
- Analyst Decision
- MODD
- VRCA Hold
- Analyst Count
- MODD 0
- VRCA 5
- Target Price
- MODD N/A
- VRCA $6.00
- AVG Volume (30 Days)
- MODD 78.5K
- VRCA 263.8K
- Earning Date
- MODD 06-20-2025
- VRCA 05-13-2025
- Dividend Yield
- MODD N/A
- VRCA N/A
- EPS Growth
- MODD N/A
- VRCA N/A
- EPS
- MODD N/A
- VRCA N/A
- Revenue
- MODD N/A
- VRCA $7,179,000.00
- Revenue This Year
- MODD N/A
- VRCA $127.85
- Revenue Next Year
- MODD N/A
- VRCA $105.09
- P/E Ratio
- MODD N/A
- VRCA N/A
- Revenue Growth
- MODD N/A
- VRCA N/A
- 52 Week Low
- MODD $0.68
- VRCA $0.38
- 52 Week High
- MODD $2.65
- VRCA $9.36
- Technical
- Relative Strength Index (RSI)
- MODD 36.37
- VRCA 43.40
- Support Level
- MODD $0.75
- VRCA $0.49
- Resistance Level
- MODD $0.90
- VRCA $0.73
- Average True Range (ATR)
- MODD 0.07
- VRCA 0.07
- MACD
- MODD -0.01
- VRCA -0.01
- Stochastic Oscillator
- MODD 29.09
- VRCA 10.77
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.